Related Experiment Videos

Integration of genomic technologies for accelerated cancer drug development

Mark Basik1, Spyro Mousses, Jeffrey Trent

  • 1Translational Genomics Research Institute, Gaithersburg, MD, USA.

Biotechniques
|September 30, 2003
PubMed

Insights

New genomic technologies offer insights into cancer but create bottlenecks. High-throughput microarray technologies can accelerate the analysis of genetic alterations and drug targets for cancer development.

Area of Science:

  • Genomics and Molecular Biology
  • Cancer Research
  • Biotechnology

Background:

  • Advanced technologies enable detailed investigation of molecular interactions in cancer.
  • Genomic discoveries have identified numerous potential drug targets.
  • Current research and development face bottlenecks due to the extensive analysis required for these targets.

Purpose of the Study:

  • To review emerging high-throughput technologies for analyzing cancer-related molecular information.
  • To discuss the application of DNA, tissue, and live-cell transfection microarrays.
  • To explore how these technologies can accelerate the translation of genomic data.

Main Methods:

  • Review of current literature on high-throughput technologies.
  • Examination of DNA, tissue, and live-cell transfection microarray applications.
  • Analysis of processes for discovering, validating, and translating genomic information.

Main Results:

  • High-throughput technologies offer solutions to the bottleneck in functional analysis of cancer targets.
  • Microarray technologies can efficiently process large volumes of data from genomic studies.
  • These methods facilitate the discovery, validation, and translation of cancer-related genetic information.

Conclusions:

  • Emerging microarray technologies are crucial for overcoming challenges in cancer drug development.
  • Efficient data processing via high-throughput methods is essential for utilizing genomic project outcomes.
  • These technologies promise to accelerate the identification and validation of novel cancer drug targets.

Related Concept Videos